Intercept

Our Statement on COVID-19

As the global COVID-19 pandemic continues to quickly evolve, Intercept has put measures in place intended to safeguard the health of our team and the patients we serve. In doing so, we are aiming to do our part to help slow the spread of COVID-19 in our communities and protect our employees and their families, all while continuing the critical work necessary to bring our approved medicines to people who need them.

- In accordance with guidance issued by the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO) and local authorities, Intercept's global workforce, both office and field-based employees, are working remotely from home. We are now leveraging digital communication technologies to continue important interactions with healthcare professionals, patients and other stakeholders.

- As always, ensuring patient access to our medicines is of paramount importance, and we are working closely with our third-party manufacturers, distributors and other trusted partners to manage our supply chain activities and mitigate any potential disruptions to our OCALIVA® (obeticholic acid or OCA) supply as a result of COVID-19.

- As a global organization with ongoing clinical trials being conducted around the world, we are monitoring the situation very closely and have taken measures intended to minimize any disruption to our trials. For example, we're conducting remote site monitoring, transportation reimbursement and arranging additional shipments of investigational product to sites. Our major Phase 3 NASH studies, REGENERATE and REVERSE, are fully enrolled. We are focused first and foremost on patient safety and are working with our contract research organizations, study sites and other partners to ensure our studies continue to be conducted in a safe manner and that study integrity is maintained.

- We remain focused on our strategic objectives for this year, which include the delivery of OCALIVA to appropriate patients, the ongoing regulatory review of our applications on file with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), and our preparations for the launch of OCA for liver fibrosis due to nonalcoholic steatohepatitis (NASH) following approval.

More than ever, we remain steadfast in our mission to build a healthier tomorrow for patients with progressive non-viral liver diseases. We are tremendously grateful to our employees, customers, partners, and other stakeholders who continue to demonstrate resolve and adaptability during this unprecedented time. We are committed to continuing to implement measures intended to minimize any potential business impact from COVID-19 and will continue to closely monitor, assess and respond to the situation as it evolves.

For additional information:

- Contact: https://www.interceptpharma.com/contact-us/
- Patient Resources: https://www.interceptpharma.com/our-focus/patient-resources/